77 results
425
EQRX
EQRx, Inc.
23 Oct 23
Business combination disclosure
6:13am
antitumor benefit. This observation supports an important part of our overall strategy for the RAS(ON) inhibitors that will be discussed later.
[Slide … patients the potential for a cure. Our strategy in expanding into earlier lines of therapy involves a multi-pronged approach that include development
DEFM14A
EQRX
EQRx, Inc.
29 Sep 23
Proxy related to merger
4:38pm
pipeline targeting critical signaling nodes within the RAS pathway and associated pathways. This cohesive approach underpins its clinical strategy
425
RVMD
Revolution Medicines Inc
1 Aug 23
Business combination disclosure
5:24pm
alternatives in the context of a revised strategy.
But from our point of view, we see significant momentum in the development of data. We have expectations
425
hboemsp1447ls6urhhg8
1 Aug 23
Business combination disclosure
5:22pm
425
w29731
1 Aug 23
Business combination disclosure
5:11pm
425
c3z5phsf81bx3kk8rr
1 Aug 23
Business combination disclosure
7:25am
8-K
EX-2.1
292i888 ncxfx7l20
1 Aug 23
Form of Parent Stockholder Voting Agreement
7:19am
425
l614i
1 Aug 23
Business combination disclosure
7:15am
8-K
apr4s6nw ezgk8ya
8 May 23
Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
wu1g68
8 May 23
Leveraging $1.3 Billion Cash Position; Reports First Quarter 2023 Financial Results
4:08pm
424B3
q3fpilvays 40
10 Nov 22
Prospectus supplement
7:24pm
8-K
EX-99.1
6gq mbav0ld0mtd6xa
10 Nov 22
EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
7:09am
DEF 14A
9rh mtlnzpor
12 Aug 22
Definitive proxy
4:05pm
424B3
k2defufi1g82
11 Aug 22
Prospectus supplement
9:21pm
8-K
EX-99.1
riblr0pa
11 Aug 22
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
7:07am